Altered antioxidant status has been implicated in schizophrenia. Microglia are major sources of free radicals such as superoxide in the brain, and play crucial roles in various brain diseases. Recent postmortem and imaging studies have indicated microglial activation in the brain of schizophrenia patients. Animal models that express some phenotypes of schizophrenia have revealed the underlying microglial pathology. In addition, minocycline, an antibiotic and the best known inhibitor of microglial activation, has therapeutic e‹cacy in schizophrenia. We have recently revealed that various antipsychotics directly aŠect microglia via proin‰ammatory reactions such as oxidative stress, by in vitro studies using rodent microglial cells. Based on theseˆndings, we have suggested that microglia are crucial players in the brain in schizophrenia, and modulating microglia may be a novel therapeutic target. In this review paper, we introduce our hypothesis based on the above evidence. The technique of in vivo molecular redox imaging is expected to be a powerful tool to clarify this hypothesis.
. Microglia Hypothesis of Schizophrenia
Microglia are activated by various immunological/in‰ammatory factors during stressful life episodes (e.g. infections and physical/psychological traumas) both in pre-and post-natal states, developmental states and other human life events. Activated microglia release free radicals and proin‰ammatory cytokines. These mediators are known to cause brain dysfunctions such as neuronal degeneration, white matter abnormalities and decreased neurogenesis. These disturbances of neuron-microglia interactions may thus be one of the crucial factors in the pathophysiology of schizophrenia. Drugs, which can modulate microglial maladaptive activation, may have therapeutic eŠects on schizophrenia patients, by reducing microglial excessive in‰ammatory/oxidative reactions. 
